Cipla Usa Drug Patent Portfolio
Cipla Usa owns 1 orange book drug protected by 4 US patents Given below is the list of Cipla Usa's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8383596 | Antibacterial aminoglycoside analogs | 02 Jun, 2031 | Active |
| US8822424 | Antibacterial aminoglycoside analogs | 21 Nov, 2028 | Active |
| US9266919 | Antibacterial aminoglycoside analogs | 21 Nov, 2028 | Active |
| US9688711 | Antibacterial aminoglycoside analogs | 21 Nov, 2028 | Active |
Latest Legal Activities on Cipla Usa's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cipla Usa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
FDA Final Eligibility Letter
Critical
| 30 Jan, 2024 | US8822424 |
|
FDA Final Eligibility Letter
Critical
| 30 Jan, 2024 | US8383596 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 23 Aug, 2023 | US9266919 |
| transaction for FDA Determination of Regulatory Review Period | 15 May, 2023 | US8383596 |
| transaction for FDA Determination of Regulatory Review Period | 15 May, 2023 | US8822424 |
| transaction for FDA Determination of Regulatory Review Period | 18 Apr, 2023 | US8383596 |
| transaction for FDA Determination of Regulatory Review Period | 18 Apr, 2023 | US8822424 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 02 Mar, 2022 | US8822424 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 28 Dec, 2020 | US9688711 |
| Second letter to regulating agency to determine regulatory review period | 24 Sep, 2020 | US8822424 |
| Second letter to regulating agency to determine regulatory review period | 24 Sep, 2020 | US8383596 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Small Entity | 28 Aug, 2020 | US8383596 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 28 Aug, 2020 | US8383596 |
|
Email Notification
Critical
| 14 May, 2020 | US8822424 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 May, 2020 | US8383596 |
Cipla Usa's Family Patents
Recent FDA approvals and tentative approvals for Cipla Usa
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Innovator drugs
Includes innovator drug submissions that appear in FDA approval and tentative approval disclosures.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Dolutegravir Lamivudine Tenofovir Alafenamide |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 4 - New Combination | 30 Mar, 2022 |
| Abacavir And Lamivudine |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 3 - New Dosage Form | 06 Apr, 2017 |
| Lopinavir And Ritonavir |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 5 - New Formulation or New Manufacturer | 21 May, 2015 |
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Bictegravir, Emtricitabine And Tenofovir Alafenamide |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 14 Oct, 2025 |
| Emtricitabine And Tenofovir Alafenamide |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 10 Oct, 2025 |
| Nintedanib |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 02 Jul, 2025 |
Explore deeper patents analysis
Cipla Usa Drug List
Given below is the complete list of Cipla Usa's drugs and the patents protecting them.
1. Zemdri
Zemdri is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8383596 | Antibacterial aminoglycoside analogs |
02 Jun, 2031
(5 years from now)
| Active |
| US8822424 | Antibacterial aminoglycoside analogs |
21 Nov, 2028
(2 years from now)
| Active |
| US9266919 | Antibacterial aminoglycoside analogs |
21 Nov, 2028
(2 years from now)
| Active |
| US9688711 | Antibacterial aminoglycoside analogs |
21 Nov, 2028
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zemdri's drug page